Abstract LB-255: Acquired and intrinsic resistance to vemurafenib in BRAF<sup>v600e</sup>-driven melanoma brain metastases
Mark C. de Gooijer(Manchester Academic Health Science Centre), Olaf van Tellingen(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Levi C.M. Buil(Cancer Genomics Centre), Gang Li(Inner Mongolia Medical University), Ping Zhang(Griffith University), Stephan Freriks(The Netherlands Cancer Institute)
Cited by 0
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
|Journal of Clinical Oncology|1993|313